Second dose of the BNT162b2 mRNA vaccine: Value of timely administration but questionable necessity among the seropositive

Konstantina Kontopoulou; Alexandra Ainatzoglou; Christos T Nakas; Athina Ifantidou; Georgia Goudi; Eleni Antoniadou; Vasilios Adamopoulos; Nikitas Papadopoulos; Georgios Papazisis

doi:10.1016/j.vaccine.2021.07.065

Second dose of the BNT162b2 mRNA vaccine: Value of timely administration but questionable necessity among the seropositive

Vaccine. 2021 Aug 23;39(36):5078-5081. doi: 10.1016/j.vaccine.2021.07.065. Epub 2021 Jul 31.

Authors

Konstantina Kontopoulou¹, Alexandra Ainatzoglou², Christos T Nakas³, Athina Ifantidou¹, Georgia Goudi⁴, Eleni Antoniadou⁵, Vasilios Adamopoulos¹, Nikitas Papadopoulos¹, Georgios Papazisis⁶

Affiliations

¹ Department of Microbiology, G. Gennimatas General Hospital, Thessaloniki, Greece.
² Department of Clinical Pharmacology, School of Medicine, Aristotle University of Thessaloniki, Greece.
³ Laboratory of Biometry, University of Thessaly, Magnesia, Greece; University Institute of Clinical Chemistry, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland.
⁴ Department of Cardiology, G. Gennimatas General Hospital, Thessaloniki, Greece.
⁵ Intensive Care Unit, G. Gennimatas General Hospital, Thessaloniki, Greece.
⁶ Department of Clinical Pharmacology, School of Medicine, Aristotle University of Thessaloniki, Greece; Clinical Trials Unit, Special Unit for Biomedical Research and Education, School of Medicine, Aristotle University of Thessaloniki, Greece. Electronic address: papazisg@auth.gr.

Abstract

This study monitored titers of neutralizing IgG against the receptor-binding domain of the SARS-CoV-2 S1 subunit 14 days post-injection of each dose of the BNT162b2 mRNA Covid-19 vaccine in 401 Greek healthcare workers aged 20-67. After the first dose, titers varied upon age and history of infection, being lower in the 50+ age group and significantly higher among the seropositive. After the second dose, immunogenicity was significantly boosted in the age 50+ and SARS-CoV-2-naïve individuals, indicating the effectuality of its timely administration, yet questioning its value among the seropositive.

Keywords: BNT162b2 mRNA vaccine; Greece; Immunogenicity; Seropositive.

MeSH terms

Antibodies, Viral
BNT162 Vaccine
COVID-19 Vaccines*
COVID-19*
Humans
Middle Aged
RNA, Messenger
SARS-CoV-2

Substances

Antibodies, Viral
COVID-19 Vaccines
RNA, Messenger
BNT162 Vaccine